Comparison	O
with	O
alkaline	B-GENE
phosphatases	I-GENE
and	O
5	B-GENE
-	I-GENE
nucleotidase	I-GENE


Serum	B-GENE
gamma	I-GENE
glutamyltransferase	I-GENE
in	O
the	O
diagnosis	O
of	O
liver	O
disease	O
in	O
cattle	O
.	O


By	O
contrast	O
,	O
secretory	B-GENE
HI	I-GENE
antibodies	I-GENE
were	O
not	O
demonstrated	O
at	O
the	O
onset	O
of	O
illness	O
in	O
any	O
of	O
the	O
patients	O
,	O
but	O
their	O
formation	O
started	O
early	O
and	O
the	O
antibodies	O
reached	O
maximal	O
levels	O
about	O
10	O
days	O
after	O
onset	O
of	O
illness	O
.	O


Takayasu	O
'	O
s	O
disease	O
:	O
association	O
with	O
HLA	B-GENE
-	I-GENE
B5	I-GENE
.	O


Selective	O
stimulation	O
of	O
central	O
alpha	B-GENE
-	I-GENE
autoreceptors	I-GENE
following	O
treatment	O
with	O
alpha	O
-	O
methyldopa	O
and	O
FLA	O
136	O
.	O


Studies	O
on	O
immunoglobulin	B-GENE
E	I-GENE
:	O
the	O
impact	O
of	O
a	O
sojourn	O
with	O
Professor	O
Dan	O
H	O
.	O


Ten	O
out	O
-	O
patients	O
with	O
pustulosis	O
palmaris	O
et	O
plantaris	O
were	O
examined	O
with	O
direct	O
immunofluorescence	O
(	O
IF	O
)	O
technique	O
for	O
deposition	O
of	O
fibrinogen	B-GENE
,	O
fibrin	B-GENE
or	O
its	O
degradation	O
products	O
(	O
FR	B-GENE
-	I-GENE
antigen	I-GENE
)	O
in	O
affected	O
and	O
unaffected	O
skin	O
,	O
together	O
with	O
heparin	O
-	O
precipitable	O
fraction	O
(	O
HPF	O
)	O
,	O
cryoglobulin	B-GENE
and	O
total	O
plasma	O
fibrinogen	B-GENE
in	O
the	O
blood	O
.	O


False	O
positive	O
amniotic	B-GENE
fluid	I-GENE
alpha	I-GENE
fetoprotein	I-GENE
levels	O
resulting	O
from	O
contamination	O
with	O
fetal	O
blood	O
:	O
results	O
of	O
an	O
experiment	O
.	O


Albumin	B-GENE
and	O
cyclic	O
AMP	O
levels	O
in	O
peritoneal	O
fluids	O
in	O
the	O
child	O


The	O
concentration	O
of	O
alpha	B-GENE
2	I-GENE
-	I-GENE
macroglobulin	I-GENE
,	O
alpha	B-GENE
1	I-GENE
-	I-GENE
antitrypsin	I-GENE
,	O
plasminogen	B-GENE
,	O
C3	B-GENE
-	I-GENE
complement	I-GENE
,	O
fibrinogen	B-GENE
degradation	I-GENE
products	I-GENE
(	O
FDP	B-GENE
)	O
and	O
fibrinolytic	O
activity	O
,	O
were	O
studied	O
in	O
the	O
aqueous	O
humour	O
and	O
serum	O
from	O
nine	O
patients	O
with	O
Fuchs	O
'	O
endothelial	O
dystrophy	O
,	O
17	O
patients	O
with	O
uncomplicated	O
senile	O
cataract	O
and	O
in	O
the	O
secondary	O
aqueous	O
from	O
six	O
cataract	O
patients	O
.	O


The	O
effect	O
of	O
CBZ	O
and	O
DPH	O
can	O
be	O
explained	O
by	O
interference	O
with	O
thyroid	O
hormone	O
binding	O
to	O
TBG	B-GENE
combined	O
with	O
enzyme	O
-	O
induced	O
increased	O
metabolic	O
clearance	O
rate	O
of	O
thyroid	O
hormones	O
without	O
homeostatic	O
maintenance	O
of	O
premedication	O
levels	O
of	O
FT4	O
and	O
FT3	O
.	O


Eight	O
hours	O
after	O
the	O
administration	O
of	O
colchicine	O
,	O
the	O
serum	B-GENE
ceruloplasmin	I-GENE
level	O
began	O
to	O
rise	O
again	O
in	O
female	O
rats	O
,	O
but	O
not	O
in	O
male	O
rats	O
.	O


Ectopic	O
ACTH	B-GENE
syndrome	O
and	O
medullary	O
thyroid	O
carcinoma	O
.	O


There	O
was	O
no	O
correlation	O
between	O
serum	B-GENE
LH	I-GENE
and	O
chronological	O
or	O
bone	O
age	O
in	O
this	O
age	O
group	O
,	O
which	O
suggests	O
that	O
the	O
correlation	O
found	O
is	O
not	O
due	O
to	O
age	O
-	O
related	O
parallel	O
phenomena	O
.	O


Effect	O
of	O
succimer	O
on	O
the	O
intensity	O
of	O
tricarboxylic	B-GENE
acid	I-GENE
dehydrogenase	I-GENE
reactions	O
in	O
the	O
brain	O
of	O
rats	O
poisoned	O
with	O
mercuric	O
chloride	O


Total	O
VO2	O
was	O
decreased	O
in	O
both	O
groups	O
during	O
severe	O
hypoxia	O
but	O
limb	O
VO2	O
was	O
maintained	O
in	O
the	O
beta	O
-	O
block	O
group	O
.	O
beta	O
-	O
Block	O
prevented	O
the	O
fall	O
in	O
total	O
and	O
limb	O
peripheral	O
resistance	O
seen	O
in	O
severe	O
hypoxia	O
but	O
did	O
not	O
alter	O
the	O
consistently	O
more	O
efficient	O
utilization	O
of	O
total	O
O2	O
delivery	O
shown	O
by	O
the	O
limb	O
in	O
comparison	O
to	O
the	O
whole	O
body	O
by	O
higher	O
O2	O
extraction	O
ratios	O
and	O
lower	O
venous	O
O2	O
pressure	O
.	O
beta	B-GENE
-	I-GENE
Vasodilator	I-GENE
receptors	I-GENE
evidently	O
played	O
an	O
active	O
part	O
in	O
the	O
vasodilatation	O
seen	O
during	O
severe	O
hypoxia	O
.	O


In	O
both	O
these	O
respects	O
,	O
however	O
,	O
the	O
DBP	B-GENE
mRNA	I-GENE
resembles	O
the	O
late	O
messengers	O
of	O
SV40	O
and	O
polyoma	O
viruses	O
.	O


Effect	O
of	O
corticosteroid	O
-	O
containing	O
antirheumatic	O
combination	O
drugs	O
on	O
endogenous	O
ACTH	B-GENE
and	O
cortisol	O
production	O
.	O


Dopamine	B-GENE
receptor	I-GENE
blockade	O
and	O
the	O
neuroleptics	O
,	O
a	O
crystallographic	O
study	O
.	O


Similarly	O
,	O
maternal	B-GENE
serum	I-GENE
somatomedin	I-GENE
A	I-GENE
was	O
significantly	O
reduced	O
in	O
rats	O
nursing	O
large	O
litters	O
.	O


High	O
levels	O
of	O
serum	O
calcitonin	B-GENE
were	O
found	O
in	O
patients	O
with	O
chronic	O
renal	O
failure	O
.	O


The	O
response	O
of	O
serum	B-GENE
GH	I-GENE
to	O
arginine	O
infusion	O
was	O
normal	O
,	O
while	O
that	O
to	O
insulin	B-GENE
-	O
induced	O
hypoglycemia	O
was	O
poor	O
.	O


Hepatic	O
oxygen	O
supply	O
and	O
selected	O
blood	O
parameters	O
were	O
recorded	O
in	O
fasted	O
male	O
rates	O
given	O
20	O
-	O
-	O
30	O
mg	O
/	O
kg	O
Escherichia	B-GENE
coli	I-GENE
endotoxin	I-GENE
intraperitoneally	O
.	O


Basal	O
FSH	B-GENE
and	O
LH	B-GENE
levels	O
were	O
significantly	O
lower	O
in	O
addicts	O
;	O
after	O
GnRH	B-GENE
stimulation	O
the	O
addicts	O
'	O
FSH	B-GENE
and	O
LH	B-GENE
values	O
increased	O
but	O
not	O
significantly	O
compared	O
to	O
controls	O
.	O


In	O
this	O
article	O
,	O
the	O
clinical	O
actions	O
of	O
the	O
principal	O
dopamine	B-GENE
receptor	I-GENE
stimulating	O
agents	O
(	O
apomorphine	O
and	O
its	O
derivatives	O
;	O
piribedil	O
,	O
rye	O
-	O
ergot	O
derivatives	O
)	O
are	O
discussed	O
on	O
the	O
basis	O
of	O
their	O
biochemical	O
and	O
pharmacological	O
properties	O
.	O


In	O
patients	O
who	O
had	O
received	O
no	O
previous	O
drug	O
treatment	O
,	O
log	O
baseline	O
plasma	B-GENE
renin	I-GENE
activity	O
and	O
change	O
in	O
mean	O
blood	O
pressure	O
after	O
SQ	O
20881	O
correlated	O
significantly	O
(	O
r	O
=	O
0	O
.	O
651	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O


Plasma	O
ion	O
changes	O
in	O
venous	O
blood	O
incubated	O
with	O
beta	B-GENE
receptor	I-GENE
blockers	O
and	O
subjected	O
to	O
tonometry	O
in	O
vitro	O
.	O


Such	O
marked	O
differences	O
are	O
found	O
occasionally	O
in	O
the	O
literature	O
:	O
heterophile	O
antibodies	O
against	O
bovine	B-GENE
gammaglobulin	I-GENE
are	O
regarded	O
as	O
responsible	O
for	O
the	O
interference	O
in	O
the	O
Sephadex	O
system	O
of	O
RIST	O
.	O


Serial	O
measurements	O
of	O
total	O
serum	O
IgE	B-GENE
appears	O
to	O
be	O
a	O
useful	O
index	O
of	O
disease	O
activity	O
in	O
ABPA	O
.	O


A	O
rise	O
of	O
hemoglobin	B-GENE
concentration	O
accompanied	O
by	O
an	O
increase	O
of	O
the	O
total	O
iron	O
in	O
the	O
blood	O
serum	O
of	O
white	O
mice	O
was	O
found	O
under	O
oxygen	O
pressure	O
of	O
4	O
atm	O
for	O
an	O
hour	O
(	O
preconvulsive	O
state	O
)	O
and	O
6	O
atm	O
(	O
convulsive	O
state	O
)	O
.	O


Carbohydrate	O
metabolism	O
and	O
the	O
semen	O
profile	O
:	O
glucose	O
,	O
insulin	B-GENE
,	O
and	O
sperm	O
studies	O
.	O


Urinary	O
excretion	O
of	O
oestrone	O
,	O
oestradiol	O
-	O
17	O
beta	O
and	O
oestriol	O
in	O
pregnancies	O
complicated	O
by	O
steroid	B-GENE
sulphatase	I-GENE
deficiency	O
.	O


Irradiation	O
of	O
human	O
blood	O
platelets	O
with	O
UV	O
-	O
A	O
in	O
vitro	O
impairs	O
their	O
ability	O
to	O
aggregate	O
after	O
challenge	O
with	O
collagen	B-GENE
.	O


We	O
measured	O
basal	O
plasma	O
prolactin	B-GENE
concentrations	O
(	O
in	O
samples	O
obtained	O
during	O
the	O
early	O
follicular	O
phase	O
)	O
in	O
25	O
normal	O
(	O
control	O
)	O
women	O
and	O
in	O
a	O
similar	O
group	O
of	O
40	O
patients	O
with	O
a	O
long	O
-	O
standing	O
history	O
of	O
infertility	O
.	O


In	O
girls	O
prolactin	B-GENE
levels	O
rise	O
at	O
stage	O
2	O
,	O
and	O
are	O
higher	O
after	O
menarche	O
;	O
in	O
boys	O
there	O
is	O
no	O
change	O
in	O
prolactin	B-GENE
levels	O
.	O


Serum	O
levels	O
of	O
IgG	B-GENE
and	O
IgM	B-GENE
were	O
also	O
raised	O
,	O
but	O
contrary	O
to	O
the	O
findings	O
of	O
other	O
observers	O
IgA	B-GENE
levels	O
were	O
normal	O
.	O


A	O
decrease	O
of	O
the	O
lysozyme	B-GENE
activity	O
coincided	O
with	O
the	O
clinical	O
improvement	O
of	O
the	O
bacterial	O
meningitis	O
.	O


These	O
responses	O
were	O
compared	O
with	O
others	O
in	O
the	O
same	O
subjects	O
under	O
the	O
same	O
conditions	O
and	O
it	O
was	O
concluded	O
that	O
the	O
antihypertensive	O
effect	O
of	O
labetalol	O
is	O
explained	O
by	O
concurrent	O
blockade	O
of	O
alpha	B-GENE
-	I-GENE
and	I-GENE
beta	I-GENE
-	I-GENE
adrenoceptors	I-GENE
.	O


Analysis	O
of	O
liver	O
biopsy	O
specimens	O
from	O
patients	O
with	O
hepatitis	O
showed	O
a	O
large	O
variation	O
in	O
the	O
mean	O
iron	O
content	O
of	O
the	O
liver	O
ferritin	B-GENE
molecules	O
.	O


The	O
effect	O
of	O
pure	O
natural	O
porcine	B-GENE
secretin	I-GENE
on	O
endocrine	O
and	O
exocrine	O
pancreatic	O
secretion	O
was	O
studied	O
in	O
the	O
totally	O
isolated	O
perfused	O
porcine	O
pancreas	O
.	O


In	O
biopsies	O
CK	B-GENE
-	I-GENE
MB	I-GENE
fraction	O
of	O
total	O
myocardial	O
CPK	B-GENE
was	O
37	O
%	O
,	O
the	O
total	B-GENE
-	I-GENE
CPK	I-GENE
activity	O
of	O
human	O
skeletal	O
muscles	O
still	O
shows	O
a	O
5	O
%	O
fraction	O
of	O
CK	B-GENE
-	I-GENE
MB	I-GENE
.	O


Treatment	O
of	O
hypertension	O
with	O
a	O
combination	O
of	O
the	O
adrenergic	B-GENE
beta	I-GENE
receptor	I-GENE
blockader	O
,	O
obsidan	O
,	O
and	O
the	O
vasodilator	O
,	O
apressin	O


Platelet	O
serotonin	O
(	O
5	O
-	O
HT	O
)	O
and	O
5	B-GENE
-	I-GENE
HT	I-GENE
releasing	I-GENE
factor	I-GENE
in	O
plasma	O
of	O
migrainous	O
patients	O
.	O


Carcinoembryonic	B-GENE
antigen	I-GENE
(	O
CEA	B-GENE
)	O
procedures	O
and	O
clinical	O
evaluation	O
.	O


A	O
diagnosis	O
of	O
MS	O
was	O
made	O
based	O
on	O
subtle	O
neurologic	O
signs	O
,	O
spinal	O
fluid	O
gamma	B-GENE
globulin	I-GENE
elevations	O
,	O
and	O
abnormalities	O
in	O
neuropsychological	O
testing	O
.	O


Recurrence	O
of	O
bladder	O
tumors	O
among	O
the	O
original	O
9	O
cases	O
has	O
occurred	O
only	O
among	O
the	O
5	O
whose	O
properdin	B-GENE
levels	O
remained	O
below	O
the	O
median	O
.	O


Treatment	O
with	O
heparin	O
,	O
plasminogen	B-GENE
activators	O
and	O
fibrinogenolytic	O
agents	O
was	O
disappointing	O
although	O
renal	O
function	O
has	O
stabilized	O
in	O
one	O
patient	O
on	O
long	O
term	O
oral	O
anticoagulant	O
therapy	O
.	O


The	O
morphological	O
effects	O
of	O
two	O
snake	O
venoms	O
,	O
N	O
.	O
naja	O
and	O
A	O
.	O
piscivorus	O
,	O
and	O
of	O
the	O
Direct	B-GENE
Lytic	I-GENE
Factor	I-GENE
and	O
Phospholipase	B-GENE
-	I-GENE
A	I-GENE
,	O
compounds	O
purified	O
from	O
N	O
.	O
naja	O
crude	O
venom	O
,	O
were	O
investigated	O
on	O
lung	O
and	O
cremaster	O
vessels	O
of	O
rats	O
.	O


Possibility	O
of	O
a	O
TSH	B-GENE
-	O
Screening	O
method	O
for	O
detection	O
of	O
hypothyroidism	O
in	O
the	O
newborn	O


RESULTS	O
:	O
Total	O
IgE	B-GENE
levels	O
showed	O
a	O
tendency	O
to	O
diminish	O
.	O


The	O
neuroleptic	O
-	O
induced	O
increase	O
in	O
central	O
DA	O
turnover	O
(	O
an	O
indicator	O
for	O
the	O
degree	O
of	O
DA	B-GENE
receptor	I-GENE
blocking	O
)	O
was	O
found	O
to	O
be	O
positively	O
correlated	O
with	O
the	O
therapeutic	O
effect	O
of	O
neuroleptics	O
and	O
the	O
development	O
of	O
hypokinetic	O
-	O
rigid	O
symptoms	O
.	O


Serum	O
gastrin	B-GENE
levels	O
did	O
not	O
change	O
in	O
either	O
group	O
;	O
however	O
,	O
background	O
serum	O
gastrin	B-GENE
concentrations	O
were	O
significantly	O
greater	O
for	O
V	O
&	O
P	O
patients	O
than	O
V	O
&	O
A	O
patients	O
throughout	O
the	O
study	O
.	O


The	O
effect	O
of	O
calcitonin	B-GENE
,	O
a	O
large	O
amount	O
of	O
calcium	O
given	O
orally	O
,	O
pentagastrin	O
and	O
glucagon	B-GENE
on	O
plasma	O
47Ca	O
radioactivity	O
curves	O
in	O
subjects	O
pretreated	O
with	O
47Ca	O
was	O
examined	O
.	O


Since	O
myoglobin	B-GENE
is	O
co	O
-	O
extracted	O
with	O
the	O
hemoglobin	B-GENE
,	O
the	O
2	O
heme	O
pigments	O
are	O
separated	O
in	O
one	O
portion	O
of	O
the	O
extract	O
by	O
precipitating	O
the	O
hemoglobin	B-GENE
in	O
an	O
85	O
%	O
(	O
NH4	O
)	O
2SO4	O
solution	O
.	O


The	O
influence	O
of	O
adrenergic	O
nerves	O
of	O
the	O
response	O
of	O
blood	O
vessels	O
in	O
the	O
rabbit	O
ear	O
to	O
2	B-GENE
-	I-GENE
-	I-GENE
phenylalanine	I-GENE
-	I-GENE
8	I-GENE
-	I-GENE
lysine	I-GENE
vasopressin	I-GENE
(	O
Octapressin	B-GENE
)	O
.	O


Fibrin	B-GENE
cloaking	O
along	O
the	O
catheter	O
was	O
found	O
in	O
20	O
patients	O
studied	O
by	O
pull	O
-	O
out	O
arteriography	O
and	O
was	O
unassociated	O
with	O
clinical	O
symptoms	O
.	O


Lymphocyte	O
subpopulations	O
,	O
serum	B-GENE
IgE	I-GENE
and	O
total	O
eosinophil	O
counts	O
in	O
patients	O
with	O
bronchial	O
asthma	O
.	O


IgG	B-GENE
levels	O
of	O
1	O
/	O
100	O
were	O
present	O
in	O
only	O
four	O
out	O
of	O
ten	O
samples	O
obtained	O
150	O
days	O
after	O
the	O
clinical	O
onset	O
.	O


The	O
other	O
hypoglycaemic	O
patient	O
showed	O
an	O
exaggerated	O
insulin	B-GENE
release	O
in	O
response	O
to	O
tolbutamide	O
.	O


Glucose	B-GENE
-	I-GENE
6	I-GENE
-	I-GENE
phosphate	I-GENE
dehydrogenase	I-GENE
(	O
G	B-GENE
-	I-GENE
6	I-GENE
-	I-GENE
PD	I-GENE
)	O
deficiency	O
in	O
the	O
newborn	O
.	O


The	O
routine	O
administration	O
of	O
fat	O
-	O
soluble	O
vitamins	O
appears	O
unnecessary	O
but	O
it	O
is	O
prudent	O
to	O
measure	O
prothrombin	B-GENE
time	O
and	O
serum	O
vitamins	O
A	O
and	O
E	O
at	O
intervals	O
.	O


Three	O
groups	O
of	O
patients	O
who	O
had	O
undergone	O
subtotal	O
thyroidectomy	O
for	O
Graves	O
'	O
s	O
disease	O
,	O
toxic	O
multinodular	O
goitre	O
,	O
or	O
euthyroid	O
multinodular	O
goitre	O
12	O
to	O
15	O
years	O
before	O
and	O
in	O
whom	O
a	O
normal	O
serum	O
thyroxine	O
(	O
T	O
-	O
4	O
)	O
level	O
was	O
found	O
were	O
each	O
divided	O
into	O
two	O
subgroups	O
on	O
the	O
basis	O
of	O
a	O
normal	O
or	O
a	O
raised	O
serum	O
thyrotrophin	B-GENE
concentration	O
.	O


Besides	O
,	O
we	O
found	O
in	O
3	O
patients	O
increased	O
serum	B-GENE
immunoglobulins	I-GENE
,	O
chiefly	O
IgG	B-GENE
,	O
as	O
first	O
Russe	O
,	O
Busey	O
and	O
Barbeau	O
demonstrated	O
in	O
a	O
large	O
French	O
-	O
Canadian	O
family	O
.	O


3	O
activities	O
of	O
the	O
factor	B-GENE
II	I-GENE
molecule	O
in	O
the	O
newborn	O
infant	O
at	O
term	O


In	O
contrast	O
,	O
the	O
insulin	B-GENE
response	O
had	O
returned	O
to	O
the	O
non	O
-	O
pregnant	O
value	O
by	O
the	O
second	O
day	O
of	O
the	O
puerperium	O
.	O


Here	O
we	O
describe	O
and	O
map	O
two	O
more	O
new	O
genes	O
identified	O
as	O
allele	O
-	O
specific	O
suppressors	O
that	O
compensate	O
for	O
carboxy	O
-	O
terminal	O
truncation	O
of	O
PET122	B-GENE
.	O


Rabbit	B-GENE
skeletal	I-GENE
muscle	I-GENE
glycogenin	I-GENE
.	O


Characterization	O
of	O
the	O
human	B-GENE
gene	I-GENE
encoding	I-GENE
cytokeratin	I-GENE
17	I-GENE
and	O
its	O
expression	O
pattern	O
.	O


A	O
statistically	O
significant	O
improvement	O
due	O
to	O
the	O
administration	O
of	O
Bromergon	O
was	O
observed	O
in	O
symptoms	O
associated	O
with	O
overreactiveness	O
to	O
normal	O
prolactin	B-GENE
levels	O
,	O
i	O
.	O
e	O
.	O
abdominal	O
tension	O
,	O
edema	O
,	O
weight	O
gain	O
and	O
breast	O
tenderness	O
.	O


In	O
7	O
of	O
9	O
cases	O
,	O
the	O
enhancer	O
is	O
fused	O
to	O
the	O
c	B-GENE
-	I-GENE
myc	I-GENE
bearing	I-GENE
sequences	I-GENE
of	O
chromosome	O
8	O
.	O


These	O
studies	O
show	O
that	O
UCRBP	B-GENE
binds	O
to	O
various	O
target	O
motifs	O
that	O
are	O
distinct	O
from	O
the	O
UCR	O
motif	O
:	O
the	O
adeno	B-GENE
-	I-GENE
associated	I-GENE
virus	I-GENE
P5	I-GENE
promoter	I-GENE
and	O
elements	O
in	O
the	O
immunoglobulin	B-GENE
light	I-GENE
-	I-GENE
and	I-GENE
heavy	I-GENE
-	I-GENE
chain	I-GENE
genes	O
,	O
as	O
well	O
as	O
elements	O
in	O
ribosomal	B-GENE
protein	I-GENE
genes	I-GENE
.	O


These	O
results	O
indicate	O
that	O
both	O
N	O
-	O
and	O
C	O
-	O
terminal	O
mutations	O
are	O
required	O
to	O
inhibit	O
transrepression	O
by	O
FBR	B-GENE
protein	I-GENE
and	O
that	O
multiple	O
structural	O
mutations	O
accompanied	O
by	O
posttranslational	O
protein	O
modification	O
alter	O
gene	O
regulation	O
by	O
FBR	B-GENE
protein	I-GENE
.	O


The	O
predicted	O
receptor	O
structure	O
includes	O
a	O
cysteine	O
-	O
rich	O
extracellular	O
domain	O
,	O
a	O
single	O
hydrophobic	O
transmembrane	O
domain	O
,	O
and	O
a	O
predicted	O
cytoplasmic	B-GENE
serine	I-GENE
/	I-GENE
threonine	I-GENE
kinase	I-GENE
domain	I-GENE
.	O


Drosophila	B-GENE
UbcD1	I-GENE
encodes	O
a	O
highly	O
conserved	O
ubiquitin	B-GENE
-	O
conjugating	O
enzyme	O
involved	O
in	O
selective	O
protein	O
degradation	O
.	O


The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
feasibility	O
of	O
retrovirus	O
mediated	O
expression	O
of	O
rp47phox	B-GENE
in	O
the	O
HL60	O
and	O
U937	O
human	O
hematopoietic	O
cell	O
lines	O
,	O
and	O
in	O
an	O
Epstein	O
-	O
Barr	O
virus	O
transformed	O
B	O
-	O
lymphocyte	O
cell	O
line	O
(	O
EBV	O
-	O
BCL	O
)	O
derived	O
from	O
a	O
p47phox	B-GENE
-	O
deficient	O
CGD	O
patient	O
.	O


Both	O
in	O
vitro	O
-	O
synthesized	O
S2	B-GENE
protein	I-GENE
and	O
synthetic	O
peptides	O
corresponding	O
to	O
S2	B-GENE
are	O
shown	O
to	O
react	O
positively	O
with	O
sera	O
obtained	O
from	O
EIAV	O
-	O
infected	O
horses	O
,	O
providing	O
the	O
first	O
direct	O
evidence	O
of	O
expression	O
of	O
this	O
protein	O
in	O
infected	O
animals	O
.	O


The	O
DNA	O
sequence	O
of	O
the	O
sulfate	B-GENE
activation	I-GENE
locus	I-GENE
from	O
Escherichia	O
coli	O
K	O
-	O
12	O
has	O
been	O
determined	O
.	O


Plasma	O
membranes	O
of	O
cultured	O
cells	O
contain	O
high	O
affinity	O
receptors	O
for	O
high	B-GENE
density	I-GENE
lipoprotein	I-GENE
(	O
HDL	B-GENE
)	O
that	O
appear	O
to	O
mediate	O
removal	O
of	O
excess	O
intracellular	O
cholesterol	O
.	O


A	O
recombinant	O
with	O
a	O
5	O
'	O
end	O
from	O
src	B-GENE
and	O
a	O
3	O
'	O
end	O
from	O
ros	B-GENE
,	O
called	O
SRC	B-GENE
x	O
ROS	B-GENE
,	O
transformed	O
chicken	O
embryo	O
fibroblasts	O
(	O
CEF	O
)	O
to	O
a	O
spindle	O
shape	O
morphology	O
,	O
mimicking	O
that	O
of	O
UR2	B-GENE
.	O


ROS	B-GENE
x	O
SRC	B-GENE
(	O
R	B-GENE
)	O
contains	O
a	O
16	O
-	O
amino	O
-	O
acid	O
deletion	O
that	O
includes	O
the	O
3	O
'	O
half	O
of	O
the	O
transmembrane	O
domain	O
of	O
ros	B-GENE
.	O


Transient	O
transfection	O
assays	O
showed	O
that	O
site	O
A	O
is	O
necessary	O
and	O
sufficient	O
for	O
RXR	B-GENE
alpha	I-GENE
-	O
mediated	O
transactivation	O
of	O
the	O
apoAI	B-GENE
gene	I-GENE
basal	I-GENE
promoter	I-GENE
in	O
human	O
hepatoma	O
HepG2	O
cells	O
in	O
the	O
presence	O
of	O
RA	O
and	O
that	O
this	O
transactivation	O
is	O
abolished	O
by	O
increasing	O
amounts	O
of	O
cotransfected	O
ARP	B-GENE
-	I-GENE
1	I-GENE
.	O


Antibodies	O
against	O
this	O
purified	O
protein	O
localize	O
RIM1	B-GENE
to	O
mitochondria	O
.	O


A	O
position	O
-	O
independent	O
activation	O
domain	O
which	O
contained	O
conserved	O
regions	O
II	O
and	O
III	O
was	O
identified	O
at	O
the	O
carboxyl	O
terminus	O
of	O
the	O
HNF	B-GENE
-	I-GENE
3	I-GENE
beta	I-GENE
protein	I-GENE
(	O
amino	O
acids	O
361	O
to	O
458	O
)	O
.	O


HNF	B-GENE
-	I-GENE
3	I-GENE
beta	I-GENE
amino	I-GENE
-	I-GENE
terminal	I-GENE
sequences	I-GENE
defined	O
by	O
conserved	O
region	O
IV	O
also	O
contributed	O
to	O
transactivation	O
,	O
but	O
region	O
IV	O
activity	O
required	O
the	O
participation	O
of	O
the	O
region	O
II	O
-	O
III	O
domain	O
.	O


The	O
hit1	B-GENE
-	I-GENE
1	I-GENE
mutation	O
caused	O
a	O
defect	O
in	O
synthesis	O
of	O
a	O
74	B-GENE
-	I-GENE
kD	I-GENE
heat	I-GENE
shock	I-GENE
protein	I-GENE
.	O


The	O
319	O
base	O
pair	O
region	O
immediately	O
upstream	O
of	O
the	O
CAP	O
site	O
is	O
characterized	O
by	O
the	O
lack	O
of	O
a	O
proximal	O
TATA	O
box	O
and	O
the	O
presence	O
of	O
sequences	O
similar	O
to	O
GC	O
boxes	O
,	O
CACCC	O
boxes	O
,	O
CCAAT	O
boxes	O
,	O
activator	B-GENE
protein	I-GENE
2	I-GENE
(	O
Ap	B-GENE
-	I-GENE
2	I-GENE
)	O
sites	O
,	O
partial	O
glucocorticoid	O
response	O
elements	O
(	O
GREs	O
)	O
,	O
and	O
partial	O
cyclic	O
AMP	O
response	O
elements	O
(	O
CREs	O
)	O
.	O


These	O
findings	O
suggest	O
that	O
the	O
MAP	B-GENE
kinase	I-GENE
activator	I-GENE
/	O
MAP	B-GENE
kinase	I-GENE
system	O
may	O
be	O
the	O
downstream	O
components	O
of	O
ras	B-GENE
signal	O
transduction	O
pathways	O
.	O


Labile	O
LTR	B-GENE
-	I-GENE
binding	I-GENE
proteins	I-GENE
appear	O
to	O
be	O
essential	O
for	O
c	B-GENE
-	I-GENE
myc	I-GENE
hyperexpression	O
,	O
since	O
both	O
LTR	O
-	O
enhanced	O
transcription	O
and	O
the	O
activities	O
of	O
LTR	B-GENE
-	I-GENE
binding	I-GENE
proteins	I-GENE
are	O
specifically	O
decreased	O
after	O
inhibition	O
of	O
protein	O
synthesis	O
(	O
A	O
.	O


Truncation	O
variants	O
of	O
peptides	O
isolated	O
from	O
MHC	B-GENE
class	I-GENE
II	I-GENE
molecules	I-GENE
suggest	O
sequence	O
motifs	O
.	O


Although	O
the	O
E	O
-	O
box	O
consensus	O
is	O
minimally	O
defined	O
as	O
CANNTG	O
,	O
the	O
adjacent	O
nucleotides	O
of	O
functional	O
E	O
-	O
boxes	O
are	O
variable	O
for	O
genes	O
regulated	O
by	O
the	O
bHLH	B-GENE
proteins	I-GENE
.	O


T	B-GENE
-	I-GENE
cell	I-GENE
receptor	I-GENE
beta	I-GENE
(	O
TCR	B-GENE
beta	I-GENE
)	O
gene	O
rearrangements	O
occur	O
in	O
a	O
third	O
of	O
early	O
B	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemias	O
(	O
ALLs	O
)	O
.	O


We	O
have	O
cloned	O
and	O
sequenced	O
COX12	B-GENE
,	O
the	O
nuclear	O
gene	O
for	O
subunit	B-GENE
VIb	I-GENE
of	O
Saccharomyces	B-GENE
cerevisiae	I-GENE
cytochrome	I-GENE
c	I-GENE
oxidase	I-GENE
.	O


The	O
basal	O
promoter	O
elements	O
of	O
murine	B-GENE
cytochrome	I-GENE
c	I-GENE
oxidase	I-GENE
subunit	I-GENE
IV	I-GENE
gene	I-GENE
consist	O
of	O
tandemly	O
duplicated	O
ets	B-GENE
motifs	O
that	O
bind	O
to	O
GABP	B-GENE
-	I-GENE
related	I-GENE
transcription	I-GENE
factors	I-GENE
.	O


The	O
minimal	O
promoter	O
of	O
the	O
RII	B-GENE
beta	I-GENE
gene	I-GENE
was	O
composed	O
of	O
two	O
adjacent	O
functional	O
elements	O
.	O


A	O
major	O
mechanism	O
whereby	O
steroid	B-GENE
hydroxylase	I-GENE
gene	I-GENE
transcription	O
is	O
regulated	O
in	O
the	O
adrenal	O
cortex	O
requires	O
the	O
pituitary	O
peptide	O
hormone	O
,	O
ACTH	B-GENE
,	O
which	O
acts	O
via	O
cAMP	O
.	O


Km	O
and	O
Vmax	O
for	O
two	O
substrates	O
,	O
src	B-GENE
-	I-GENE
related	I-GENE
peptide	I-GENE
and	O
poly	O
(	O
Glu	O
,	O
Tyr	O
)	O
(	O
4	O
:	O
1	O
)	O
,	O
were	O
2	O
.	O
4	O
mM	O
and	O
2	O
.	O
5	O
mumol	O
min	O
-	O
1	O
mg	O
-	O
1	O
and	O
0	O
.	O
26	O
mM	O
and	O
1	O
.	O
2	O
mumol	O
min	O
-	O
1	O
mg	O
-	O
1	O
,	O
respectively	O
.	O


The	O
ORF1	O
protein	O
was	O
found	O
to	O
be	O
highly	O
homologous	O
to	O
the	O
putative	O
potexvirus	B-GENE
RNA	I-GENE
replicases	I-GENE
;	O
ORF2	O
,	O
-	O
3	O
,	O
-	O
5	O
and	O
-	O
6	O
proteins	O
also	O
have	O
analogues	O
among	O
the	O
potex	O
-	O
and	O
/	O
or	O
carlavirus	O
-	O
encoded	O
proteins	O
.	O


Characterization	O
of	O
the	O
regulon	O
controlled	O
by	O
the	O
leucine	B-GENE
-	I-GENE
responsive	I-GENE
regulatory	I-GENE
protein	I-GENE
in	O
Escherichia	O
coli	O
.	O


This	O
mutation	O
also	O
results	O
in	O
markedly	O
decreased	O
levels	O
of	O
CAD	B-GENE
mRNA	I-GENE
and	O
protein	O
in	O
the	O
mutant	O
.	O


Thus	O
,	O
the	O
pol	B-GENE
alpha	I-GENE
-	O
primase	B-GENE
complex	O
appears	O
to	O
act	O
processively	O
for	O
only	O
a	O
short	O
distance	O
.	O


